FASN and prostate carcinoma: Using LNCaP-LN3 prostate cancer cells, Oh et al. demonstrated that FASN inhibition by FAS inhibitors (TVB-3166, GSK2194069, and Fasnall) results in metabolic alterations in [132], which may negatively affect the cancer’s metabolic reprogramming and survival.